News
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
16 Jun 24
News, Top Stories, Movers
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
14 Jun 24
Earnings, News, Pre-Market Outlook, Markets, Trading Ideas
Reported Earlier, Avidity Biosciences Prices $400.9M Public Offering Of 10.55M Common Shares At $38/Share
14 Jun 24
News
Avidity Up 33% on Rare Muscle Disease Study Results
13 Jun 24
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Markets, Analyst Ratings, Trading Ideas, General
B of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $45
13 Jun 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Avidity Biosciences, Raises Price Target to $46
12 Jun 24
News, Price Target, Analyst Ratings
Crude Oil Moves Higher; Vera Bradley Shares Slide
12 Jun 24
News, Eurozone, Commodities, Intraday Update, Markets, Trading Ideas
Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $45
12 Jun 24
News, Price Target, Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45
12 Jun 24
News, Price Target, Analyst Ratings
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Jun 24
Movers
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
12 Jun 24
Why Avidity Biosciences Shares Are Trading Higher Wednesday
12 Jun 24
News, Movers
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
12 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
Market-Moving News for June 12th
12 Jun 24
Movers, Trading Ideas
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Jun 24
Movers
Avidity Reports Over 50% Reduction In DUX4 Regulated Genes In Phase 1/2 FORTITUDE Trial For Facioscapulohumeral Muscular Dystrophy
12 Jun 24
News
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
10 Jun 24
Analyst Ratings
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
10 Jun 24
News, Price Target, Reiteration, Analyst Ratings
Avidity Biosciences To Present Preliminary Data From Phase 1/2 FORTITUDE Trial Of AOC 1020 In People Living With Facioscapulohumeral Muscular Dystrophy At The 31st Annual FSHD Society International Research Congress
29 May 24
Biotech, News, General
Press releases
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
17 Jun 24
Offerings, Press Releases
Avidity Biosciences to Participate in Upcoming Investor Conference
14 Jun 24
Press Releases
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
13 Jun 24
Offerings, Press Releases
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
12 Jun 24
Offerings, Press Releases
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
12 Jun 24
Press Releases
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
29 May 24
Press Releases
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 May 24
Press Releases
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
15 May 24
Press Releases
Vicore Expands and Strengthens its Board of Directors
14 May 24
Biotech, News, Press Releases
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
8 May 24
Press Releases
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Apr 24
Press Releases
Avidity Biosciences to Participate in Upcoming Investor Conferences
27 Mar 24
Press Releases
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 24
Press Releases